474 related articles for article (PubMed ID: 22920042)
1. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
2. Perspectives in the treatment of multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Lucia E; Vigna E; Morabito F
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S1-22. PubMed ID: 23692500
[TBL] [Abstract][Full Text] [Related]
3. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
4. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
6. Novel generation of agents with proven clinical activity in multiple myeloma.
Mateos MV; Ocio EM; San Miguel JF
Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
[TBL] [Abstract][Full Text] [Related]
7. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
8. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
9. Safety issues and management of toxicities associated with new treatments for multiple myeloma.
Brioli A; Mügge LO; Hochhaus A; Von Lilienfeld-Toal M
Expert Rev Hematol; 2017 Mar; 10(3):193-205. PubMed ID: 28116920
[TBL] [Abstract][Full Text] [Related]
10. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
11. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
12. Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.
Ocio EM; Mateos MV; San-Miguel JF
Expert Opin Investig Drugs; 2012 Aug; 21(8):1075-87. PubMed ID: 22621161
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
15. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Usmani SZ; Lonial S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
[TBL] [Abstract][Full Text] [Related]
16. [Novel targeted therapy in multiple myeloma].
Izumi T
Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Kaufman JL; Fabre C; Lonial S; Richardson PG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):370-6. PubMed ID: 23787122
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
